
Opinion|Videos|July 31, 2024
The Heterogeneity of Prostate Cancer
Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
Choosing salvage therapy after prostate cancer focal ablation
5




















